Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Frontage Laboratories, Inc. ("Frontage"), a leading global CRO/CDMO, is pleased to welcome Dr. Chandra Prakash, Ph.D., as Senior Advisor, Clinical Services. Dr. Prakash is internationally recognized for his scientific leadership in drug metabolism and pharmacokinetics (DMPK), clinical pharmacology, biotransformation, bioanalysis, and translational ADME sciences. Over his 40‑year career, he has made significant contributions to the mechanistic understanding of drug disposition, metabolic pathways
As Asian markets navigate the complexities of rising energy costs and inflationary pressures, investors are increasingly looking for opportunities that offer growth potential at lower entry points. Penny stocks, though an older term, remain relevant today as they often represent smaller or newer companies with untapped potential. By identifying those with strong financials and a promising growth path, investors can uncover valuable opportunities in this segment of the market.
Frontage Laboratories, Inc. ("Frontage"), a leading global CRO/CDMO, today announced the completion of the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd. ("Teddy Lab"), a leading clinical research laboratory service provider in China. The acquisition aims to enhance Frontage's global laboratory service capabilities and further strengthen its presence in China and the Asia-Pacific region.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.